Meyer-Schwickerath R - Search Results

1

Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy.

Spranger J, Bühnen J, Jansen V, Krieg M, Meyer-Schwickerath R, Blum WF, Schatz H, Pfeiffer AF. Spranger J, et al. Among authors: meyer schwickerath r. Horm Metab Res. 2000 May;32(5):196-200. doi: 10.1055/s-2007-978621. Horm Metab Res. 2000. PMID: 10871161

2

[TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy].

Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. Spranger J, et al. Med Klin (Munich). 1995 Mar 1;90(3):134-7. Med Klin (Munich). 1995. PMID: 7723714 German.

3

Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown.

Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Pfeiffer A, et al. Diabetes. 1997 Sep;46 Suppl 2:S26-30. doi: 10.2337/diab.46.2.s26. Diabetes. 1997. PMID: 9285495 Review.

4

Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease.

Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. Spranger J, et al. Exp Clin Endocrinol Diabetes. 1999;107(1):21-8. doi: 10.1055/s-0029-1212068. Exp Clin Endocrinol Diabetes. 1999. PMID: 10077351

5

Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.

Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Lösche C, Röllmann R, Schatz H. Meyer-Schwickerath R, et al. J Clin Invest. 1993 Dec;92(6):2620-5. doi: 10.1172/JCI116877. J Clin Invest. 1993. PMID: 7504689 Free PMC article.

6

Downregulation of serum IGF-1 for treatment of early worsening of diabetic retinopathy: a long-term follow-up of two cases.

Chantelau E, Meyer-Schwickerath R, Klabe K. Chantelau E, et al. Among authors: meyer schwickerath r. Ophthalmologica. 2010;224(4):243-6. doi: 10.1159/000260231. Epub 2009 Nov 24. Ophthalmologica. 2010. PMID: 19940532

7

Reversion of 'early worsening' of diabetic retinopathy by deliberate restoration of poor metabolic control.

Chantelau E, Meyer-Schwickerath R. Chantelau E, et al. Among authors: meyer schwickerath r. Ophthalmologica. 2003 Sep-Oct;217(5):373-7. doi: 10.1159/000071355. Ophthalmologica. 2003. PMID: 12913330

8

Insulin, insulin analogues and diabetic retinopathy.

Chantelau E, Kimmerle R, Meyer-Schwickerath R. Chantelau E, et al. Among authors: meyer schwickerath r. Arch Physiol Biochem. 2008 Feb;114(1):54-62. doi: 10.1080/13813450801900553. Arch Physiol Biochem. 2008. PMID: 18465359 Review.

9

[Development of neovascularization of the optic papilla, retina and iris. Dependence on site and extent of retinal ischemia].

Nahberger D, Meyer-Schwickerath R, Saygili O, Gronemeyer U. Nahberger D, et al. Among authors: meyer schwickerath r. Ophthalmologe. 2000 Jun;97(6):422-8. doi: 10.1007/s003470070092. Ophthalmologe. 2000. PMID: 10916386 German.

10

New insights into the pathogenesis of diabetic retinopathy--hormonal rather than metabolic factors are important.

Chantelau E, Volaco A, Meyer-Schwickerath R. Chantelau E, et al. Among authors: meyer schwickerath r. Vasa. 2004 Nov;33(4):205-10. doi: 10.1024/0301-1526.33.4.205. Vasa. 2004. PMID: 15623194 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters